vineyard glp 1 JoinVineyard (@joinvineyard) • Facebook Weight loss with GLP-1 medicines

The OR for nuclear cataract (366 eyes) comparing the third quartile of glycemic index scores with the first quartile (OR = 1.64, 95% CI = 1.02-2.65) was significant, but there was not a consistent dose-response association

Reasons patients give for stopping include reaching a plateau in weight loss, inability to tolerate side effects, or even inability to get the medication due to shortages

RTs Three Key Takeaways: Strong Response Subtype : Research presented at the 2026 ATS International Conference identified a subgroup of patients who experienced nearly twice the improvement in sleep apnea severity compared to other participants

PMCID: PMC4863553